Target's General Information
Target ID T62460
Target Name Janus kinase 1 (JAK-1)
Synonyms Tyrosine-protein kinase JAK1; JAK1B; JAK1A
Target Type Successful
Gene Name JAK1
Biochemical Class Kinase
UniProt ID JAK1_HUMAN
Target's Expression Profile in Disease Related Tissue between Patients and Normal People
Disease Psoriasis
Example drug Baricitinib Phase 3 [1], [2], [3], [4]
Tissue Skin
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.21
Z-score: -0.36
P-value: 2.16E-02
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: 0.3
Z-score: 0.52
P-value: 1.87E-07
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Polycythemia vera
Example drug Ruxolitinib Phase 2 [3], [4], [5], [6]
Tissue Whole blood
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.28
Z-score: -1.07
P-value: 6.35E-07
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Rheumatoid arthritis
Example drug Filgotinib Phase 2 [3], [4], [7], [8]
Tissue Synovial tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 1.54
Z-score: 3.33
P-value: 5.55E-05
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Target's Expression Profile across Various Tissues of Healthy Individual
References
REF 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7792).
REF 2 ClinicalTrials.gov (NCT02265705) A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA). U.S. National Institutes of Health.
REF 3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF 4 NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.
REF 5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5688).
REF 6 ClinicalTrials.gov (NCT01493414) INC424 for Patients With Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. U.S. National Institutes of Health.
REF 7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7913).
REF 8 ClinicalTrials.gov (NCT02048618) Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.